Iambic, a clinical-stage life science and technology company leveraging AI for drug discovery, has struck a multi-year collaboration with Takeda to advance high-priority small molecule programs. 

 

The partnership will initially focus on Takeda’s Oncology and Gastrointestinal & Inflammation therapeutic areas and gives Takeda access to Iambic’s NeuralPLexer, a leading model for predicting protein-ligand complexes.

 

“Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates,” said Tom Miller, Co-Founder and CEO of Iambic. 

 

“This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”

 

Chris Arendt, Chief Scientific Officer and Head of Research at Takeda, added, “We are excited to be able access Iambic’s proprietary computational platform while we work with their team to develop small molecule therapeutics with the potential to address critical unmet patient needs. 

 

"At Takeda, our focus is on accelerating the development of impactful new medicines by leveraging cutting-edge science, including the latest advances in artificial intelligence. Iambic’s small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve probability of success, and more quickly advance select programs from early project start to IND.”

 

Under the deal, Iambic will receive upfront, research, and technology access payments, and is eligible for success-based payments that could exceed $1.7 billion, plus royalties on any resulting product sales. The collaboration will combine Iambic’s AI models with its high-throughput, fully integrated wet lab capabilities, enabling a rapid Design-Make-Test-Analyze cycle that could accelerate program advancement.